Dey and coworkers [75] recently targeted the FGF receptors (FGFR) using tyrosine kinase inhibitors to decrease the activity of AKT and ERK kinases, inducing apoptosis in breast cancer cell lines. Here, AKT1 is linked to breast cancer.